Heartland Group Holdings (HGH) / HY23

Revenue up 10.2% but NPAT held to 2.4% as tax rate jumps to 29.5%

A 6.4% PBT gain and a 16.2% lift in underlying NPAT diverge from the statutory 2.4%, while ROE slips despite a materially larger balance sheet.

Release date
28 February 2023
Published
21 April 2026

What changed

Net operating income rose 10.2% to NZD 144.2m, but earnings growth compressed down the P&L: PBT rose 6.4% to NZD 69.0m and statutory NPAT rose just 2.4% to NZD 48.7m. The wedge between PBT and NPAT reflects an effective tax rate that stepped up to 29.5% from 26.8%. On management's underlying measure, NPAT was NZD 54.7m, a 16.2% lift implying roughly NZD 6.0m of one-off items excluded from the underlying figure (not itemised in the supplied extract).

The balance sheet expanded sharply. Total assets grew 24.0% to NZD 7.44bn, total liabilities grew 23.0% to NZD 6.42bn, and equity rose 30.5% to NZD 1.02bn, consistent with the FY22 equity raise. Gross borrowings stood at NZD 6.33bn (deposits NZD 4.07bn, other borrowings NZD 2.26bn), and cash climbed to NZD 385.3m from NZD 207.7m. Operating cash flow swung to a NZD 262.2m inflow from a NZD 142.3m outflow in HY22 — a funding-flow driven figure typical of a lender rather than a cash-earnings signal. Interim dividend was flat at 5.5 cents per share.

What matters

  • Tax and dilution are eating the operating growth. PBT growth of 6.4% is the cleaner operating read; the 2.4% statutory NPAT outcome combines higher tax with a much larger equity base. ROE slipped to 10.8% from 12.0%, so earnings are not yet scaling with the enlarged capital.
  • Underlying vs statutory gap. The NZD 6.0m adjustment lifts underlying NPAT growth to 16.2%, but the release, as excerpted, does not bridge the components. The quality of that uplift cannot be independently assessed from the filing extract.
  • Balance-sheet growth is the real story. A 24% lift in assets and deposits now at NZD 4.07bn (from NZD 3.33bn) shows funding-led expansion. Whether this translates into NIM-preserving receivables growth is the key forward lever, and the extract does not disclose current-period NIM or segment results.

Expectations

No quantitative guidance or stated medium-term target is disclosed in the supplied extract. On seasonality, HY22 represented 46.6% of FY22 revenue and 50.0% of FY22 NPAT, so the business has not historically been materially second-half weighted. Annualising HY23 revenue at NZD 288.3m sits only 2.8% above the FY22 base of NZD 280.6m — a softer trajectory than the 10.2% headline suggests, because the FY22 anchor already captured a stronger 2H. On NPAT, annualised HY23 of NZD 97.3m implies only low-single-digit growth over FY22's NZD 95.1m unless 2H margins improve.

Quality of result

For a deposit-taking lender, operating cash flow movements are dominated by funding and receivables flows, so the swing from negative NZD 142.3m to positive NZD 262.2m is not a cash-earnings signal. Capex was modest at NZD 7.7m (5.4% of revenue).

The durable components are the 10.2% revenue lift and 6.4% PBT growth; the less durable components are the underlying-NPAT adjustments (NZD 6.0m, not broken out) and the ROE decline that accompanies the equity raise. The flat DPS against a 30.5% larger equity base implies a higher cash-payout burden going forward unless NPAT re-accelerates — the interim payout ratio on statutory NPAT is already around 75%.

Unresolved

  • What are the components of the NZD 6.0m underlying-to-statutory reconciliation, and are they recurring in nature?
  • Why did the effective tax rate step up by 2.7pp, and is that level the new run-rate?
  • Current-period segment results, NIM, and cost-to-income ratio are not in the supplied extract, so it is not possible to see whether Motor, Reverse Mortgages, Business or Australia drove the revenue lift, or whether margin is compressing as deposits repriced.
  • Prior-period gross borrowings are not disclosed, so the change in net debt and the deposit-vs-wholesale funding mix trend cannot be measured.

This briefing cannot assess NIM, current-period segment performance, or the composition of underlying adjustments, because those disclosures are not present in the supplied extract.

Key metrics

← Swipe to view more
Metric HY23 HY22 Change
Revenue $144.2m $130.8m +10.2% ↑
Net profit after tax $48.7m $47.5m +2.4% ↑
Net cash inflow from operating activities $262.2m −$142.3m +284.3% ↑
Interim dividend per share 5.5c 5.5c flat
Cash and cash equivalents $385.3m $207.7m +85.5% ↑
Total assets $7437.9m $5998.9m +24.0% ↑

Reference: annolyse.ai/briefings/hgh-hy23

Segment breakdown

← Swipe to view more
Segment Current revenue Prior revenue Current result Mix shift
Motor $36.4m n/a
Reverse Mortgages $15.3m n/a
Personal Lending $5.3m n/a
Business $37.3m n/a
Rural $15.5m n/a
Australia $21.0m n/a

Reference: annolyse.ai/briefings/hgh-hy23

Analytical metrics

← Swipe to view more
Metric HY23 HY22 Context
PBT growth +6.4%
Effective tax rate 29.5% 26.8%
FCF pre-lease $254.4m −$150.9m +$405.3m
FCF / NPAT 522.9% -317.5% complementary conversion metric
Capex % revenue 5.4% 6.6%
Capex −$7.7m −$8.6m +$0.8m
Net debt $5943.8m
Gross borrowings $6329.1m
Payout ratio vs NPAT 75.3%
Payout ratio vs FCF pre-lease 14.4% covered
ROE (annualised) 10.8% 12.0% Weakening
HY22 share of FY22 revenue 46.6% Other half was 53.4%
HY22 share of FY22 NPAT 50.0% Other half was 50.0%
Profit from continuing operations $48.7m $47.5m +$1.1m

Reference: annolyse.ai/briefings/hgh-hy23


This analysis was generated using Annolyse, an AI-powered tool that analyses NZX/ASX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Metric context

Trajectory before this result

A compact view of the company's recent revenue and margin path, derived from the same metrics history that powers the company page.

HGH revenue trajectory

Revenue context before the current result.

HGH EBITDA margin

Earnings margin across covered periods.

Appendix

Reference material

Company materials considered in this briefing.

Current period

Heartland - 1H2023 HGH Financial Statements

HY23 / financial report

Heartland - 1H2023 Results Announcement Template

HY23 / results announcement

Heartland - 1H2023 Results Release

HY23 / results release

Prior comparable period

Heartland - 1H2022 Results Release

HY22 / results release

Heartland - HGH Financial statements

HY22 / financial report

Heartland - NZX Results Announcement (template form)

HY22 / results announcement

Full-year context

Results Announcement Template

FY22 / results announcement

Heartland FY22 Results and Offer Announcement

FY22 / results release

Heartland Group Holdings Financial Statements

FY22 / financial report

Email updates

Want briefings like this for the next reporting season?

Get the next Annolyse briefing by email when it is published.